The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...